Terns Pharmaceuticals, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026A large company bought Terns, meaning shareholders received payment and the company is no longer independent.
This speeds up drug development and approval for a leukemia treatment, potentially bringing revenue faster.
Shows how much money the company made or lost and what it owns, helping investors understand financial health.
Documents the deal structure for Merck's purchase of Terns, explaining how the transaction works.
Changes the terms of a drug licensing deal, which can affect future revenue and development timelines.
Stocky reads Terns Pharmaceuticals, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Terns Pharmaceuticals, Inc.'s most recent tracked filing was a 8-K on 5 May 2026: Merck acquires Terns Pharmaceuticals for full ownership.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.